Septic Cardiomyopathy: From Basics to Management Choices

Area of Science:

• Cardiology
• Critical Care Medicine
• Pathophysiology

Background:

• Septic cardiomyopathy (SCM) is a recognized complication of septic shock, characterized by reversible left ventricular systolic dysfunction.
• SCM is associated with a significantly poorer prognosis, increasing mortality rates to 70%-90% in septic shock patients.
• The incidence of SCM in septic shock ranges from 18% to 40%.

Purpose of the Study:

• To review the current understanding of septic cardiomyopathy (SCM) in septic shock.
• To discuss the pathogenesis, diagnosis, and management strategies for SCM.
• To highlight the prognostic implications of SCM in critically ill patients.

Main Methods:

• Review of existing literature on septic cardiomyopathy.
• Analysis of diagnostic criteria, including echocardiographic findings (e.g., LVEF <45%, RV dilatation).
• Evaluation of therapeutic interventions, comparing levosimendan with dobutamine and exploring advanced rescue strategies.

Main Results:

• SCM presents as left ventricular systolic dysfunction in septic shock patients.
• Diagnosis is aided by bedside transthoracic echocardiography.
• Levosimendan demonstrates favorable hemodynamic effects without increasing myocardial oxygen demand compared to dobutamine.

Conclusions:

• Septic cardiomyopathy is a critical complication of septic shock with high mortality.
• Understanding its pathogenesis, involving toxins, cytokines, and mitochondrial dysfunction, is key.
• Effective management involves early diagnosis and appropriate therapeutic choices, including potential rescue therapies for severe cases.